Evidence map›Paper›PMID 22761948›Full record

ArticlePloS one2012

High avidity antibodies to full-length VAR2CSA correlate with absence of placental malaria.

Yeung Lo Tutterrow, Ali Salanti, Marion Avril, Joseph D Smith, Ian S Pagano, Simon Ako, Josephine Fogako, Rose G F Leke, Diane Wallace Taylor

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  3. Trial
  4. Exploring theFrontiers in immunology · 2025
    Article
  5. Development of high affinity antibodies toFrontiers in immunology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. VAR2CSA-Mediated Host Defense Evasion ofFrontiers in immunology · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Yeung Lo TutterrowDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawai'i-Mānoa, Honolulu, Hawaii, United States of America.
Ali Salanti
Marion Avril
Joseph D Smith
Ian S Pagano
Simon Ako
Josephine Fogako
Rose G F Leke
Diane Wallace Taylor
Université de Yaoundé I · CMCenter for Infectious Disease Research · USUniversity of Hawaiʻi at Mānoa · USUniversity of Copenhagen · DKUniversity of Hawaii System · US

Funding

Shared TechnologyU19AI089688 · NIAID · UNIVERSITY OF WASHINGTON · PI RATHOD, PRADIPSINH K. · 2010 to 2023
$22.4M
Malarial Immunity in Pregnant Cameroonian WomenR01AI071160 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI TAYLOR, DIANE WALLACE · 2007 to 2011
$3.0M
TH2 BIAS EFFECT ON MALARIAL IMMUNITY IN CAMEROONU01AI043888 · NIAID · GEORGETOWN UNIVERSITY · PI TAYLOR, DIANE WALLACE · 1998 to 2002
$2.7M
Intramural NIH HHSNIAID NIH HHS R01 AI071160NIAID NIH HHS R01AI071160NIAID NIH HHS U01 AI043888NIAID NIH HHS U19 AI089688NIAID NIH HHS U19AI089688NIAID NIH HHS UO1AI43888
6 · The paper itself

Abstract

VAR2CSA mediates sequestration of Plasmodium falciparum-infected erythrocytes in the placenta, increasing the risk of poor pregnancy outcomes. Naturally acquired antibodies (Ab) to placental parasites at delivery have been associated with improved pregnancy outcomes, but Ab levels and how early in pregnancy Ab must be present in order to eliminate placental parasites before delivery remains unknown. Antibodies to individual Duffy-binding like domains of VAR2CSA have been studied, but the domains lack many of the conformational epitopes present in full-length VAR2CSA (FV2). Thus, the purpose of this study was to describe the acquisition of Ab to FV2 in women residing in high and low transmission areas and determine how Ab levels during pregnancy correlate with clearance of placental parasites. Plasma samples collected monthly throughout pregnancy from pregnant women living in high and low transmission areas in Cameroon were evaluated for Ab to FV2 and the proportion of high avidity Ab (i.e., Ab that remain bound in the presence of 3M NH(4)SCN) was assessed. Ab levels and proportion of high avidity Ab were compared between women with placental malaria (PM(+)) and those without (PM(-)) at delivery. Results showed that PM(-) women had significantly higher Ab levels (p = 0.0047) and proportion of high avidity Ab (p = 0.0009) than PM(+) women throughout pregnancy. Specifically, women with moderate to high Ab levels (>5,000 MFI) and those with ≥ 35% high avidity Ab at 5-6 months were found to have 2.3 (95% CI, 1.0-4.9) and 7.6-fold (p = 0.0013, 95% CI: 1.2-50.0) reduced risk of placental malaria, respectively. These data show that high levels of Ab to FV2, particularly those with high avidity for FV2, produced by mid-pregnancy are important in clearing parasites from the placenta. Both high Ab levels and proportion of high avidity Ab to FV2 may serve as correlates of protection for assessing immunity against placental malaria.

Indexed as

Antibody AffinityAdultAntigens, ProtozoanFemaleHumansMalaria, FalciparumPregnancyPregnancy Complications, ParasiticAntigens, ProtozoanVAR2CSA protein, Plasmodium falciparum

Identifiers

PMID22761948
PMCPMC3383675
OpenAlexW1988696596

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.